While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
Separation of glutathione S-transferases from rat liver cytosol by chromatofocusing
And we provide the care you need to live your healthiest life
This information may assist future evaluations and help identify patternswhether the symptoms improve, worsen, or fluctuate
For these situations you must see your GP
Talking openly with your healthcare team is key to good care after gastric bypass